We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Sangamo (SGMO) This Earnings Season?
Read MoreHide Full Article
Sangamo Therapeutics, Inc. (SGMO - Free Report) is expected to report third-quarter 2018 results early next month.
The company has a mixed track record. Its metrics missed estimates in two of the last four quarters while surpassed the same in the remaining two with an average negative surprise of 37.74%. Last reported quarter, Sangamo lagged estimates with a negative surprise of 13.33%.
Shares of Sangamo have lost 19.8% year to date, in line with the industry’s decrease.
Let’s see, how things are shaping up for this announcement.
Factors to Consider
With no approved product in its portfolio at the moment, Sangamo primarily generates collaboration revenues from agreements with Pfizer (PFE - Free Report) , Kite Pharma — a subsidiary of Gilead — and Bioverativ, a newly acquired unit of Sanofi.
Sangamo is developing SB-525, its gene therapy product candidate for hemophilia A, in partnership with Pfizer. In August, the company presented encouraging preliminary data from the phase I/II Alta study on SB-525 for treating hemophilia A. Sangamo and Pfizer expect to report detailed data from the study in the fourth quarter of 2018.
Sangamo’s zinc finger nuclease (ZFN) in-vivo genome editing candidate is SB-913. It is currently being evaluated in a phase I/II CHAMPIONS study for the treatment of Mucopolysaccharidosis Type II (MPS II). In September 2018, the company presented 16-week data, which demonstrated reductions in urinary glycosaminoglycans (GAGs), a key biomarker of MPS II disease pathophysiology.
Another similar candidate, SB-318, is currently being examined in a phase I/II EMPOWERS study for treating MPS I.
Additionally, the gene-edited cell therapy candidate, ST-400, is currently being investigated in phase I/II Thales study for the treatment of patients with transfusion-dependent beta-thalassemia.
In February 2018, Sangamo signed a collaborative agreement with Kite Pharma, Inc., a subsidiary of Gilead, for developing gene-edited cell therapies to address cancer, using its ZFN technology platform.
Sangamo closed its previously announced acquisition of France’s TxCell S.A., in October. Notably, TxCell develops innovative platforms for personalized T-cell immunotherapies for treating severe inflammatory and autoimmune diseases. The company expects the buyout to be a great strategic fit as it will expand its footprint in the field of CAR-Treg cell therapies for tackling such diseases.
Earnings Whispers
Our proven model does not conclusively show that Sangamo is likely to beat estimates this to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Sangamo has an Earnings ESP of 0.00%. This is because the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 13 cents each. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Sangamo currently carries a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some biotech stocks that you may want to consider as per our model, these have the right combination of elements to beat on earnings this reporting season.
Emergent BioSolutions Inc. (EBS - Free Report) has an Earnings ESP of +16.76% and a Zacks Rank #2. The company is scheduled to report third-quarter results on Nov 1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
What's in Store for Sangamo (SGMO) This Earnings Season?
Sangamo Therapeutics, Inc. (SGMO - Free Report) is expected to report third-quarter 2018 results early next month.
The company has a mixed track record. Its metrics missed estimates in two of the last four quarters while surpassed the same in the remaining two with an average negative surprise of 37.74%. Last reported quarter, Sangamo lagged estimates with a negative surprise of 13.33%.
Shares of Sangamo have lost 19.8% year to date, in line with the industry’s decrease.
Let’s see, how things are shaping up for this announcement.
Factors to Consider
With no approved product in its portfolio at the moment, Sangamo primarily generates collaboration revenues from agreements with Pfizer (PFE - Free Report) , Kite Pharma — a subsidiary of Gilead — and Bioverativ, a newly acquired unit of Sanofi.
Sangamo is developing SB-525, its gene therapy product candidate for hemophilia A, in partnership with Pfizer. In August, the company presented encouraging preliminary data from the phase I/II Alta study on SB-525 for treating hemophilia A. Sangamo and Pfizer expect to report detailed data from the study in the fourth quarter of 2018.
Sangamo’s zinc finger nuclease (ZFN) in-vivo genome editing candidate is SB-913. It is currently being evaluated in a phase I/II CHAMPIONS study for the treatment of Mucopolysaccharidosis Type II (MPS II). In September 2018, the company presented 16-week data, which demonstrated reductions in urinary glycosaminoglycans (GAGs), a key biomarker of MPS II disease pathophysiology.
Another similar candidate, SB-318, is currently being examined in a phase I/II EMPOWERS study for treating MPS I.
Additionally, the gene-edited cell therapy candidate, ST-400, is currently being investigated in phase I/II Thales study for the treatment of patients with transfusion-dependent beta-thalassemia.
In February 2018, Sangamo signed a collaborative agreement with Kite Pharma, Inc., a subsidiary of Gilead, for developing gene-edited cell therapies to address cancer, using its ZFN technology platform.
Sangamo closed its previously announced acquisition of France’s TxCell S.A., in October. Notably, TxCell develops innovative platforms for personalized T-cell immunotherapies for treating severe inflammatory and autoimmune diseases. The company expects the buyout to be a great strategic fit as it will expand its footprint in the field of CAR-Treg cell therapies for tackling such diseases.
Earnings Whispers
Our proven model does not conclusively show that Sangamo is likely to beat estimates this to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Sangamo has an Earnings ESP of 0.00%. This is because the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 13 cents each. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Sangamo currently carries a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Sangamo Therapeutics, Inc. Price and EPS Surprise
Sangamo Therapeutics, Inc. Price and EPS Surprise | Sangamo Therapeutics, Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider as per our model, these have the right combination of elements to beat on earnings this reporting season.
CRISPR Therapeutics AG (CRSP - Free Report) is expected to release third-quarter results on Nov 14. The company has an Earnings ESP of +3.53% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent BioSolutions Inc. (EBS - Free Report) has an Earnings ESP of +16.76% and a Zacks Rank #2. The company is scheduled to report third-quarter results on Nov 1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>